Sagimet Biosciences IncNASDAQ:SGMT
- LAST PRICE5.7800
- TODAY'S CHANGE (%)-0.0700 (-1.1966%)
- Bid / Lots5.7700/ 6
- Ask / Lots5.8000/ 6
- Open / Previous Close5.7700 / 5.8500
- Day Range
- 52 Week Range
- Volume441,214
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | SGMT |
|---|---|---|
| 09:32 ET | 12034 | 5.785 |
| 09:33 ET | 5327 | 5.705 |
| 09:35 ET | 24045 | 5.9 |
| 09:37 ET | 1863 | 5.85 |
| 09:39 ET | 4950 | 5.84 |
| 09:42 ET | 3600 | 5.79 |
| 09:44 ET | 8508 | 5.8 |
| 09:46 ET | 11528 | 5.93 |
| 09:48 ET | 1100 | 5.92 |
| 09:50 ET | 404 | 5.9 |
| 09:51 ET | 600 | 5.89 |
| 09:53 ET | 200 | 5.89 |
| 09:55 ET | 2716 | 5.82 |
| 09:57 ET | 570 | 5.86 |
| 10:00 ET | 100 | 5.86 |
| 10:04 ET | 936 | 5.85 |
| 10:06 ET | 2290 | 5.83 |
| 10:08 ET | 200 | 5.815 |
| 10:09 ET | 1808 | 5.85 |
| 10:11 ET | 3718 | 5.88 |
| 10:13 ET | 2200 | 5.91 |
| 10:15 ET | 5084 | 5.87 |
| 10:18 ET | 5791 | 5.86 |
| 10:20 ET | 500 | 5.85 |
| 10:22 ET | 350 | 5.84 |
| 10:24 ET | 1000 | 5.8492 |
| 10:26 ET | 200 | 5.82 |
| 10:27 ET | 220 | 5.84 |
| 10:29 ET | 400 | 5.85 |
| 10:31 ET | 8407 | 5.85 |
| 10:33 ET | 328 | 5.876 |
| 10:36 ET | 913 | 5.87 |
| 10:38 ET | 100 | 5.87 |
| 10:40 ET | 6225 | 5.9 |
| 10:42 ET | 1318 | 5.87 |
| 10:44 ET | 2402 | 5.84 |
| 10:45 ET | 7775 | 5.85 |
| 10:47 ET | 170 | 5.86 |
| 11:00 ET | 1974 | 5.8992 |
| 11:02 ET | 1256 | 5.9 |
| 11:03 ET | 2417 | 5.885 |
| 11:05 ET | 900 | 5.89 |
| 11:07 ET | 100 | 5.89 |
| 11:09 ET | 600 | 5.89 |
| 11:12 ET | 3578 | 5.8649 |
| 11:16 ET | 14266 | 5.795 |
| 11:18 ET | 1056 | 5.82 |
| 11:20 ET | 300 | 5.8168 |
| 11:21 ET | 700 | 5.83 |
| 11:23 ET | 2100 | 5.82 |
| 11:25 ET | 6576 | 5.78 |
| 11:27 ET | 100 | 5.78 |
| 11:32 ET | 1003 | 5.79 |
| 11:36 ET | 1654 | 5.7983 |
| 11:38 ET | 3100 | 5.82 |
| 11:39 ET | 2250 | 5.79 |
| 11:41 ET | 6147 | 5.84 |
| 11:43 ET | 200 | 5.81 |
| 11:45 ET | 100 | 5.815 |
| 11:48 ET | 873 | 5.79 |
| 11:50 ET | 1000 | 5.77 |
| 11:52 ET | 2900 | 5.8 |
| 11:54 ET | 2200 | 5.83 |
| 11:56 ET | 3696 | 5.88 |
| 11:59 ET | 678 | 5.8749 |
| 12:01 ET | 19366 | 5.79 |
| 12:03 ET | 300 | 5.79 |
| 12:06 ET | 100 | 5.82 |
| 12:10 ET | 754 | 5.8 |
| 12:12 ET | 100 | 5.795 |
| 12:14 ET | 1100 | 5.815 |
| 12:15 ET | 250 | 5.81 |
| 12:17 ET | 400 | 5.82 |
| 12:19 ET | 6873 | 5.7587 |
| 12:21 ET | 500 | 5.75 |
| 12:24 ET | 1445 | 5.74 |
| 12:28 ET | 100 | 5.75 |
| 12:30 ET | 1015 | 5.7505 |
| 12:32 ET | 100 | 5.7503 |
| 12:33 ET | 1080 | 5.775 |
| 12:35 ET | 579 | 5.76 |
| 12:39 ET | 1109 | 5.76 |
| 12:42 ET | 2160 | 5.72 |
| 12:44 ET | 3147 | 5.75 |
| 12:46 ET | 3430 | 5.7201 |
| 12:48 ET | 6900 | 5.7 |
| 12:50 ET | 3859 | 5.681197 |
| 12:51 ET | 250 | 5.6602 |
| 12:53 ET | 3100 | 5.6952 |
| 12:55 ET | 800 | 5.715 |
| 12:57 ET | 209 | 5.7 |
| 01:00 ET | 5470 | 5.7 |
| 01:02 ET | 425 | 5.6832 |
| 01:06 ET | 1219 | 5.6921 |
| 01:08 ET | 400 | 5.69 |
| 01:09 ET | 100 | 5.6909 |
| 01:11 ET | 1539 | 5.68 |
| 01:18 ET | 200 | 5.7 |
| 01:24 ET | 937 | 5.7 |
| 01:26 ET | 200 | 5.71 |
| 01:27 ET | 700 | 5.72 |
| 01:31 ET | 200 | 5.73 |
| 01:36 ET | 5100 | 5.72 |
| 01:38 ET | 6536 | 5.69 |
| 01:40 ET | 255 | 5.7 |
| 01:44 ET | 5991 | 5.66 |
| 01:45 ET | 3178 | 5.6601 |
| 01:47 ET | 2300 | 5.67 |
| 01:49 ET | 867 | 5.67 |
| 01:51 ET | 100 | 5.68 |
| 01:54 ET | 875 | 5.68 |
| 01:56 ET | 4729 | 5.68 |
| 02:00 ET | 1058 | 5.67 |
| 02:02 ET | 2651 | 5.68 |
| 02:03 ET | 3038 | 5.69 |
| 02:05 ET | 3278 | 5.68 |
| 02:07 ET | 5300 | 5.68 |
| 02:09 ET | 2625 | 5.69 |
| 02:12 ET | 1000 | 5.7 |
| 02:14 ET | 500 | 5.685 |
| 02:16 ET | 2400 | 5.73 |
| 02:18 ET | 2114 | 5.71 |
| 02:20 ET | 2100 | 5.715 |
| 02:21 ET | 1940 | 5.74 |
| 02:23 ET | 230 | 5.7221 |
| 02:27 ET | 700 | 5.74 |
| 02:34 ET | 350 | 5.7301 |
| 02:36 ET | 3660 | 5.76 |
| 02:38 ET | 400 | 5.74 |
| 02:41 ET | 2239 | 5.75 |
| 02:45 ET | 864 | 5.715 |
| 02:48 ET | 1200 | 5.73 |
| 02:50 ET | 100 | 5.72 |
| 02:52 ET | 200 | 5.73 |
| 02:54 ET | 7493 | 5.725 |
| 02:56 ET | 14416 | 5.74 |
| 02:57 ET | 11279 | 5.76 |
| 02:59 ET | 4986 | 5.79 |
| 03:01 ET | 700 | 5.78 |
Today
DJ Sagimet Biosciences Initiated at Buy by UBS, from 6 hours ago by Dow Jones
6 hours ago by Dow Jones
Nov 7, 2024
Sagimet Biosciences to Participate in the UBS Global Healthcare Conference, from 7:30AM ET on Thursday Nov 07, 2024 by Dow Jones
7:30AM ET on Thursday Nov 07, 2024 by Dow Jones
Oct 31, 2024
DJ Sagimet Biosciences Price Target Maintained With a $32.00/Share by HC Wainwright & Co., from 5:49AM ET on Thursday Oct 31, 2024 by Dow Jones
5:49AM ET on Thursday Oct 31, 2024 by Dow Jones
Oct 29, 2024
Oct 16, 2024
Sagimet Biosciences Announces Upcoming Presentations at AASLD - The Liver Meeting(R) 2024, from 7:00AM ET on Wednesday Oct 16, 2024 by Dow Jones
7:00AM ET on Wednesday Oct 16, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Sagimet Biosciences Inc | 188.3M | -4.9x | --- |
Inhibikase Therapeutics Inc | 188.8M | -0.9x | --- |
Black Diamond Therapeutics Inc | 191.3M | -2.4x | --- |
Greenwich Lifesciences Inc | 184.8M | -17.3x | --- |
Acumen Pharmaceuticals Inc | 193.5M | -2.4x | --- |
Gossamer Bio Inc | 194.1M | -2.5x | --- |
Company Information
Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. The Company's lead drug candidate, denifanstat, is an oral, once-daily pill and the selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). In addition to MASH, the Company is evaluating denifanstat in acne and in select forms of cancer, disease areas in which dysregulation of fatty acid metabolism also plays a key role. Denifanstat is being tested in a Phase III clinical trial for moderate to severe acne vulgaris, and a Phase III trial for recurrent glioblastoma multiforme (GBM) in combination with bevacizumab.
Contact Information
- Headquarters
- 155 BOVET RD., SUITE 303SAN MATEO, CA, United States 94402
- Phone
- 650-561-8600
- Fax
- 302-730-1370
Executives
- Executive Chairman of the Board
- George Kemble
- President, Chief Executive Officer, Director
- David Happel
- Chief Financial Officer
- Thierry Chauche
- Chief Compliance Officer, General Counsel
- Elizabeth Rozek
- Chief Medical Officer
- Eduardo Martins
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $188.3M |
|---|---|
Revenue (TTM) | $2.0M |
Shares Outstanding | 32.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.18 |
Book Value | $3.98 |
P/E Ratio | -4.9x |
Price/Sales (TTM) | 94.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,813.75% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
